Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy

American Journal of Kidney Diseases

Volumn 61, Issue 3, 2013, Pages 490-500

  Scoville, Bridget A ^a   Mueller, Bruce A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antibiotics; critical illness; infection; pharmacodynamics; Pharmacokinetics; renal replacement therapy

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CLAVULANIC ACID; CREATININE; DAPTOMYCIN; GENTAMICIN; HYPERTENSIVE FACTOR; INOTROPIC AGENT; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SEDATIVE AGENT; TICARCILLIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PENETRATION; FLUID BALANCE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; KIDNEY DISEASE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOADING DRUG DOSE; MALE; MENTAL HEALTH; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; RENAL REPLACEMENT THERAPY; RESPIRATORY FUNCTION DISORDER; TACHYCARDIA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; UROSEPSIS;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; HUMANS; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

EID: 84874118661     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.08.042     Document Type: Article

References (107)

1. Centers for Disease Control and Prevention National hospital ambulatory medical care survey: 2008 emergency department summary tables http://www.cdc.gov/nchs/data/ahcd/nhames-emergency/2008-ed-web-tables.pdf Accessed April 5, 2012
2. S.S. Taber, B.A. Mueller Drug-associated renal dysfunction Crit Care Clin 22 2 2006 357 374
3. S. Uchino, J. Kellum, R. Bellomo Acute renal failure in critically ill patients: a multinational, multicenter study JAMA 294 7 2005 813 818
4. M.J. Tobin Principles and Practice of Mechanical Ventilation 2nd ed. 2006 McGraw-Hill Inc New York, NY
5. N.R. MacIntyre, D.J. Cook, E.W. Ely Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine Chest 120 suppl 6 2001 375S 395S
6. J.A. Kellum, N. Lamiere KDIGO clinical practice guideline for acute kidney injury http://www.kdigo.org/clinical-practice-guidelines/pdf/ KDIGO%20AKI%20Guideline.pdf Accessed April 5, 2012
7. M.H. Kollef, G. Sherman, S. Ward, V.J. Fraser Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients Chest 115 2 1999 462 474
8. S.R. Bauer, C. Salem, M.J. Connor Jr Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT Clin J Am Soc Nephrol 7 3 2012 452 457
9. L. Seyler, F. Cotton, F.S. Taccone Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy Crit Care 15 3 2011 R137
10. A.A. Udy, J.M. Varghese, M. Altukroni Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough concentrations Chest 142 1 2012 30 39
11. J.A. Roberts, P. Kruger, D.L. Paterson, J. Lipman Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36 8 2008 2433 2440
12. W.A. Craig Does the dose matter? Clin Infect Dis 33 suppl 3 2001 S233 S237
13. G. Woodrow, J.H. Turney Cause of death in acute renal failure Nephrol Dial Transplant 7 3 1992 230 234
14. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 1 2007 79 86
15. W. Craig Pharmacokinetic-pharmacodynamic parameters: rationale for antibacterial dosing in mice and men Clin Infect Dis 26 1 1998 1 12
16. M. Rybak, B.M. Lomaestro, J.C. Rotschafer Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Pharmacotherapy 29 11 2009 1275 1279
17. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, P.F. Pierce Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob Agents Chemother 45 10 2001 2793 2797
18. R.D. Moore, C.R. Smith, P.S. Lietman The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia J Infect Dis 149 3 1984 443 448
19. M.E. Levison Pharmacodynamics of antimicrobial drugs Infect Dis Clin North Am 18 3 2004 451 465
20. P.S. McKinnon, J.A. Paladino, J.J. Schentag Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 4 2008 345 351
21. G.W. Patel, N. Patel, A. Lat Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections Diagn Microbiol Infect Dis 64 2 2009 236 240
22. J.A. Roberts, J. Lipman, S. Blot, J. Rello Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 14 4 2008 390 396
23. R.P. Dellinger, M.M. Levy, J.M. Carlet Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 8 2008 296 327
24. J. Jacobi, G.L. Fraser, D.B. Coursin Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult Crit Care Med 30 1 2002 119 141
25. M. Valtonen, E. Tiula, O. Takkunen, J.T. Backman, P.J. Neuvonen Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure J Antimicrob Chemother 48 6 2001 881 885
26. T.S. van der Werf, P.O. Mulder, J.G. Zijlstra, D.R. Uges, C.A. Stegeman Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH) Intensive Care Med 23 8 1997 873 877
27. T.C. Hardin, S.C. Butler, S. Ross, J.H. Wakeford, J.H. Jorgensen Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity Pharmacotherapy 14 2 1994 147 152
28. R.F. Eyler, M. Heung, M. Pleva The pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill subjects receiving CVVHD and/or ECMO Pharmacotherapy 2012 In press
29. D.J. Askenazi, D.T. Selewski, M.L. Paden Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation [published online ahead of print April 12 Clin J Am Soc Nephrol 2012 http://dx.doi.org/10. 2215/CJN.12731211
30. J.T. Kielstein, S. Tolk, C. Hafer Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatment BMC Nephrol 12 2011 15
31. R.F. Eyler, B.A. Mueller Antibiotic dosing in critically ill patients with acute kidney injury Nat Rev Nephrol 7 4 2011 226 235
32. B. Heintz, G. Matzke, W. Dager Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis Pharmacotherapy 29 5 2009 562 577
33. M.D. Churchwell, B.A. Mueller Drug dosing during continuous renal replacement therapy Semin Dial 22 2 2009 185 188
34. G.R. Aronoff, W.M. Bennett, J.S. Berns Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children 5th ed. 2007 American College of Physicians Philadelphia, PA
35. R. Trotman, J. Williamson, D. Shoemaker, W. Salzer Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy Clin Infect Dis 41 8 2005 1159 1166
36. U.F. Kroh Drug administration in critically ill patients with acute renal failure N Horiz 3 4 1995 748 759
37. P. Reetze-Bonorden, J. Böhler, E. Keller Drug dosage in patients during continuous renal replacement therapy Pharmacokinetic and therapeutic considerations Clin Pharmacokinet 24 5 1993 362 379
38. S. Vaara, V. Pettila, K.M. Kaukonen Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy Acta Anaesthesiol Scand 56 2 2012 147 157
39. A.M. Li, C.D. Gomersall, G. Choi, Q. Tian, G.M. Joynt, J. Lipman A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 64 5 2009 929 937
40. L. Vidal, M. Shavit, A. Fraser, M. Paul, L. Leibovici Systematic comparison of four sources of drug information regarding adjustment of dose for renal function BMJ 331 7511 2005 263
41. B.A. Mueller, W.E. Smoyer Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy Clin Pharmacol Ther 86 5 2009 479 482
42. G.R. Matzke, G.R. Aronoff, A.J. Atkinson Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 80 11 2011 1122 1137
43. M.M. Finucane, G.A. Stevens, M.J. Cowan National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants Lancet 377 9765 2011 557 567
44. M.P. Pai Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults [published online ahead of print June 18 Pharmacotherapy 2012 http://dx.doi.org/10.1002/j.1875-9114.2012.01108.x
45. D.M. Roberts, J.A. Roberts, M.S. Roberts Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study Crit Care Med 40 5 2012 1523 1528
46. F.P. Wilson, J.S. Berns Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD) Clin Nephrol 77 4 2012 329 331
47. W.R. Clark, B.A. Mueller, K.J. Alaka, W.L. Macias A comparison of metabolic control by continuous and intermittent therapies in acute renal failure J Am Soc Nephrol 4 7 1994 1413 1420
48. W.R. Clark, B.A. Mueller, M.A. Kraus, W.L. Macias Extracorporeal therapy requirements of patients with acute renal failure J Am Soc Nephrol 8 5 1997 804 812
49. H. Schiffl, S.M. Lang, R. Fischer Daily hemodialysis and the outcome of acute renal failure N Engl J Med 346 5 2002 305 310
50. Vancomycin [package insert] 2011 APP Pharmaceuticals Schaumburg, IL
51. Vibativ [package insert] 2012 Theravance Inc South San Francisco, CA
52. Cefazolin [package insert] 2011 Sagent Pharmaceuticals Schaumburg, IL
53. Colistimethate [package insert] 2010 X-Gen Pharmaceuticals Inc Big Flats, NY
54. Rocephin [package insert] 2010 Genentech USA Inc South San Francisco, CA
55. Ciprofloxacin Injection [package insert] 2011 Sagent Pharmaceuticals Schaumburg, IL
56. Amikacin [package insert] 2008 Abbott Laboratories Abbott Park, IL
57. US Food and Drug Administration Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis and impact on dosing and labeling http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf Accessed April 5, 2012
58. N.A. Mason, B.L. Neudeck, L.S. Welage, J.A. Patel, R.D. Swartz Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration Clin Nephrol 60 2 2003 96 104
59. M.K. Scott, W.L. Macias, M.A. Kraus, W.R. Clark, M.A. Carfagna, B.A. Mueller Effects of dialysis membrane on intradialytic vancomycin administration Pharmacotherapy 17 2 1997 256 262
60. N.N. Salama, J.H. Segal, M.D. Churchwell Intradialytic administration of daptomycin in end-stage renal disease patients on hemodialysis Clin J Am Soc Nephrol 4 7 2009 1190 1194
61. N. Patel, K. Cardone, D. Grabe Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis Antimicrob Agents Chemother 55 4 2011 1677 1683
62. N.N. Salama, J.H. Segal, M.D. Churchwell Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients Nephrol Dial Transplant 25 2010 1279 1284
63. Cubicin [package insert] 2010 Cubist Pharmaceuticals Inc Lexington, MA
64. Gentamicin sulfate [package insert] 2008 APP Pharmaceuticals LLC Schaumburg, IL
65. Merrem [package insert] 2010 AstraZeneca Pharmaceuticals LP Wilmington, DE
66. Zosyn [package insert] 2009 Wyeth Pharmaceuticals Inc Philadelphia, PA
67. K.M. Sowinski, S.J. Magner, A. Lucksiri, M.K. Scott, R.J. Hamburger, B.A. Mueller Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing Clin J Am Soc Nephrol 3 2 2008 355 361
68. O.H. Kamel Mohamed, I.M. Wahba, S. Watnick Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen Clin J Am Soc Nephrol 2 4 2007 694 699
69. M.G. Sinnollareddy, M.S. Roberts, J. Lipman, J.A. Roberts Beta-lactam pharmacokinetics/pharmacodynamics in critically ill patients and strategies for dose-optimisation - a structured review Clin Exp Pharmacol Physiol 39 6 2012 489 496
70. J.T. Kielstein, M. Schiffer, C. Hafer Back to the future: extended dialysis for treatment of acute kidney injury in the intensive care unit J Nephrol 23 5 2010 494 501
71. D. Fliser, J.T. Kielstein Technology insight: treatment of renal failure in the intensive care unit with extended dialysis Nat Clin Pract Nephrol 2 1 2006 32 39
72. M.R. Marshall, T. Ma, D. Galler, A.P. Rankin, A.B. Williams Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy Nephrol Dial Transplant 19 4 2004 877 884
73. M.R. Marshall, T.A. Golper, M.J. Shaver, M.G. Alam, D.K. Chatoth Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy Am J Kidney Dis 39 3 2002 556 570
74. J.T. Kielstein, U. Kretschmer, T. Ernst Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study Am J Kidney Dis 43 2 2004 342 349
75. A.N. Berbece, R.M. Richardson Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal Kidney Int 70 5 2006 963 968
76. B.A. Mueller, B.A. Scoville Adding to the armamentarium: antibiotic dosing in extended dialysis Clin J Am Soc Nephrol 7 3 2012 373 375
77. J.A. Roberts, R.L. Mehta, J. Lipman Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing? Crit Care Med 39 3 2011 602 603
78. B. Decker, B.A. Mueller, K.M. Sowinski Drug dosing considerations in alternative hemodialysis Adv Chronic Kidney Dis 14 3 2007 e17 e26
79. J.M. Lorenzen, M. Broll, V. Kaever Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis Clin J Am Soc Nephrol 7 3 2012 385 390
80. O. Burkhardt, S. Thon, J. Burhenne, T. Welte, J.T. Kielstein Suphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis Int J Antimicrob Agents 36 1 2010 93 94
81. S. Swoboda, M.C. Ober, C. Lichtenstern Pharmacokinetics of linezolid in septic patients with and without extended dialysis Eur J Clin Pharmacol 66 3 2010 291 298
82. E. Cremaschi, U. Maggiore, C. Maccari, C. Cademartiri, R. Andreoli, E. Fiaccadori Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED) Minerva Anestesiol 76 11 2010 961 964
83. J.A. Roberts, J. Field, A. Visser Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury Antimicrob Agents Chemother 54 9 2010 3635 3640
84. J.T. Kielstein, C. Engber, S.M. Bode-Boeger Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis - a pharmacokinetic study Nephrol Dial Transplant 25 5 2010 1537 1541
85. J.T. Kielstein, J. Lorenzen, V. Kaever Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis - a single case Nephrol Dial Transplant 24 7 2009 2283 2285
86. L. Golestaneh, A. Gofran, M.H. Mokrzycki, J.L. Chen Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing Clin Nephrol 72 4 2009 286 291
87. O. Burkhardt, C. Hafer, A. Langhoff Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis Nephrol Dial Transplant 24 1 2009 267 271
88. D. Czock, C. Husig-Linde, A. Langhoff Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis Clin J Am Soc Nephrol 1 6 2006 1263 1268
89. J.T. Kielstein, D. Czock, T. Schopke Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis Crit Care Med 34 1 2006 51 56
90. Q. Tian, C.D. Gomersall, M. Ip, P.E. Tan, G.M. Joynt, G.Y. Choi Adsorption of amikacin, a significant mechanism of elimination by hemofiltration Antimicrob Agents Chemother 52 3 2008 1009 1013
91. D.A. Pasko, M.D. Churchwell, N.N. Salama, B.A. Mueller Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy Blood Purif 32 2 2011 82 88
92. A.M. Vilay, M. Grio, D.D. DePestel Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis Crit Care Med 39 1 2011 19 25
93. A. Spooner, O. Corrigan, M. Donnelly A pharmacokinetic basis for improving therapeutic outcomes of aminoglycoside therapy during continuous venovenous hemodiafiltration Crit Care 11 suppl 2 2007 P101
94. M.E. Deldot, J. Lipman, S.E. Tett Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration Br J Clin Pharmacol 58 3 2004 259 268
95. F. Thalhammer, P. Schenk, H. Burgmann Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration Antimicrob Agents Chemother 42 9 1998 2417 2420
96. M.S. Joy, G.R. Matzke, R.F. Frye, P.M. Palevsky Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Am J Kidney Dis 31 6 1998 1019 1027
97. B.J. Zarowitz, J.V. Anandan, F. Dumler, J. Jayashankar, N. Levin Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients J Clin Pharmacol 26 8 1986 686 689
98. The RENAL Replacement Therapy Study Investigators Intensity of continuous renal-replacement therapy in critically ill patients N Engl J Med 361 17 2009 1627 1638
99. S. Vesconi, D.N. Cruz, R. Fumagalli Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury Crit Care 13 2 2009 R57
100. The VA/NIH Acute Renal Failure Trial Network Intensity of renal support in critically ill patients N Engl J Med 359 1 2008 7 20
101. J.T. Kielstein Dosage of renal replacement therapy in acute renal failure Dtsch Med Wochenschr 34 35 2009 1697 1699
102. J.T. Kielstein, O. Burkhardt, S.M. Bode-Boeger Dose matters: dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy Crit Care Med 37 8 2009 2491 2492
103. N. Patel, M.H. Scheetz, G.L. Drusano, T.P. Lodise Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients Antimicrob Agents Chemother 54 1 2010 460 465
104. T.P. Lodise, B. Lomaestro, G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 3 2007 357 363
105. T.P. Lodise, B.M. Lomaestro, G.L. Drusano Society of Infectious Diseases Pharmacists Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases pharmacists Pharmacotherapy 26 9 2006 1320 1332
106. G. Brandhorst, M. Oellerich, G. Maine, P. Taylor, G. Veen, P. Wallemacq Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem 58 5 2012 821 825
107. E.V. Granowitz, R.B. Brown Antibiotic adverse reactions and drug interactions Crit Care Clin 24 2 2008 421 442